Jermall Charlo Withdrawn from Title Fight, Jaime Munguia Takes His Place
Jermall Charlo has been withdrawn from his scheduled fight against Armando Resendiz for the WBA super middleweight title, scheduled for May 2nd. The decision, motivated by undisclosed reasons, has led to the incorporation of Jaime Munguia as a replacement.
The news of Charlo’s withdrawal came shortly after his participation in the co-main event was confirmed, where he was to face Resendiz in Las Vegas. The main event will feature Gilberto “Zurdo” Ramirez’s defense of the unified cruiserweight title against David Benavidez.
Munguia, former super welterweight champion, will now have the opportunity to fight for the title.
The fight will be part of PBC’s pay-per-view event on Prime Video, which will take place at the T-Mobile Arena.
Negotiations for Resendiz to defend his title against Charlo began a month ago, after a possible match against Munguia fell through. Resendiz, who won the interim title after a surprising victory over Caleb Plant last May, was promoted to absolute champion after Terence Crawford’s retirement in December. Charlo, for his part, had participated in the same card, achieving a technical knockout victory over Thomas LaManna, ending a period of 18 months of inactivity.
After defeating Plant, Resendiz will seek to consolidate his victory by defeating another prominent name in his first defense of the WBA title.
Resendiz, 27 years old, made a name for himself by knocking out Jarrett Hurd in 2023. However, his momentum was affected when he was stopped by Elijah Garcia in his next fight. After returning to the path of victory against Fernando Paliza, he received the opportunity to face Plant, although he was initially considered an opponent before surprising the former super middleweight champion.
Munguia (45-2, 35 KOs) hasn’t fought since May 2025, when he obtained a unanimous decision over Bruno Surace. The victory was initially in jeopardy after Munguia tested positive for a banned substance following a post-fight urine analysis, but the failed test was later deemed a false positive.
